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The e&f+ of early cemnary recaanilli7atiun on the plarma In the 16 patients witk :I prltent infarct-lelatcd artery at 
kvek of two Qrsceagutant acute phase Qroteio% the fast- 90 min. infarct size estimaed by integrated 24 h CK MB, 
peting Qkadttow actiMlor inhibitor and van Wi!lehrand time for ST w_m,ment levation to dec~rase tohallmaximum 
fae(or, were ktveotigated in 24 patient3 with myocmdii and ppak C-resrtive Qrotrin were reduced cignitirantty 
infarction rfetvtng tntravenous rPeDmbinant ti.u”bt)pr ptas. 
mklogca activator (rt.PA, within 6 h Of the ompt al syolp- 
toas. Cornnary nngiagrpphy wa performed before and 90 
ml0 after the start of rt.PA infusion. Continuous etectmcar- valor inhibitor activil) on day 2 (p = 0.05) ai day 3 
diographic remrdimgs and 4 h plosmn ereatine kinw MB tp = 0.01) and loner 0 to 12 h awwd wit Willebrand 
&omzyiw (CK MB) were pwformxt over the first 24 h. fzsr,cw ,p = 0.01,. 
Plasma piavminogeo aclivator iohihitor actirity, ran Wiir Thus. early cororay rwanalization curtatts the FE- 
b+amJ factw and C-reactive protein were nwared t&xv roonre of ~tasminoepn wti.mtor inhibitor wtivitv and van 
*-PA k&ion, daily for the first 3 days nnd nRer 90 days. tiillobnmh factor G mycardial infarction, mosi likely by 
In Ike entire group, plasmioogen activator inhibitor reducing the extent of isckmia and necrosis and the 
activity p&d at 24 h (day I), represent@ a significant consequent acute phase rewtioo. By blunting the early 
increase over values at all other times (p = 0.03). “on postinfarction pmcoagulant state, prompt recanaittion 
Wtlkbrnnd factor WBF higher in the tint 2 days of tnfarc- may reduce the risk of thrombcembolic comptieations in 
tiw mmpnrcd with atier 90 days (Q = 0.W). C.reacti”e the first days aher myrxnrdial infantian. 
protein poked on day 2, with an eightfold i”cIwIse over N Am Coil Cardiol1!?20:16:1553-60) 
v&es on admission (p = O.OtU). 
Rapid changes in the concentration of several plasma pro- 
teins are a major feature of the acute phase reaction induced 
by tissue damage (I). C-reactive QrOtein i> a fast and widely 
Ructuaring acute phase reactant; its plasma concentraion 
rxovides n sensitive althouch nonspecific indication of the 
hegrce of xute phase res,,, aid generally reflects the 
extent of tissue damage (2). A number of other proteins 
whose plasma concentratiotn change in the acute phase are 
involved tn the process of thrombogenesis; among these are 
the fast-acting plasminogen activator inhibitor-l and van 
Willebrand factor (3-S). 
Plasmmogen activator inhibitor-l, by neutrdliring both 
urokinase-type and tissue-type plasminogen activator (t- 
PA). effectively inhibits fibrinolysis and protects clots from 
early lysis (61. Significantly higher plasma concentrations of 
the fast-acting plasminogen activator inhibitor have been 
found in patients with a previous myocardial infarCtiOn 
compared with values in age-matched control subjects (71. 
even in the presence of angiognphically normal coronary 
arteries (0. and in oatients with o first mvocardial infarction 
who later have a new infarction comp&ed with values in 
patieftts who do not (9). voo Willebrand factor mediates 
&telet adhesion to exposed sohendothclium. thereby pro- 
motingthe formation ofplatelet thrombus at sitesof vascular 
injury, and forms a noncovaleot cootplex with facicr Vii1 
(IO). Higher plasma wnccntrarions of van Willebmod factor 
have been found in women with myocardbl infarction before 
45 years of age (I 1) than in age- 2nd gender-matcf.cd control 
subjects. 
Raised plasma levels of plasminogen a.!ivator inhibitor 
activity and van Willebrand factor have been reported 
(12-15) during the acute phase of myocardial infarction, 
when they may favor the persistence or recorrmce of 
introcoronary thrombosis and the development of extracor- 
ovary tbromhoembolic complications. It is not known 
whether successful thrombolysis. through the reduction of 
infarct size. can reduce the amplitude or duration of this 
procoagulant state. In the present study. we investigated 
whether early coronary patency after thrombolytic therapy 
is associated with a reduction in the response ofplasminogen 
activator inhibitor-l and van Willchmod factor in the first 
days after myocardial iofarcrion. 
Methods 
Shdyptieolr. Patients were considered for admission to 
the study if they had chest pail; of X0 min duration that was 
associated with electrocardiographic (ECG) changes afcarly 
evolving acute myocardial infarction (ST segment elevation 
>0.2 mV in at least 2 leads ofthe standard I2 lead ECG) and 
it did not resolve atzra 2 to 4 mg intravenous bolos injection 
of isosorbide dinitrate. Pdtienls were excluded if they had 
chest pain lastiog >6 h. cardiogcnic shock, contraindications 
to thromholytic therapy, childbearing potential or were >75 
years old. The study group consisted of 24 patients. The 
study protocol was approved by our institutional ethics 
committee. All patients gave informed consent to oarticioate 
in the study. 
F’mtocoI. A continuous 24 b ECG recording (Marquette 
8N) of the two leads showing the grerdest ST segment 
elevation was begun. An intravenous infusion of I to IO mglh 
of isosorbide dinitrotc. titrated against blood pressure, was 
commenced and maintained for 24 b. Coronary angiography 
was Performed soon after admission before (time 0) and 
90 min after the start of thrombolrtic treatment. An intrave- 
nous bolos injection of heparin (S.ooO 1U) was administered 
at the start of cardiac cathctcrizalion; full hcparin therapy. 
resulting in an activated panial tbmmboplastin time between 
two and three times the control valoc.‘was begun immedi- 
ately after the first catheterization and continued for 24 h. 
Patency of the infarct-related artery was assessed by two 
independent observers according 10 the Thrombolysis in 
Myocardial Infarction (TIMI) perfusion criteria (16). Coro- 
nary occlusion was defined as itMI grade 0 or I and patency 
as TIMI grade 2 or 3. Subtotal occlusion was defined or the 
presence of arteriographic filling defects auegestive of in- 
ttaluminal thrombus despiie TIM! grade 2 or 3 patency. 
Dortble chain recombinanr tissrre-type plasmbmgen ocri- 
war frf-PA] (Wel!wmc Foundation Ltd.. Beekenham, En- 
gland) (17) was adninistcrcd intravenously within 6 h of the 
onset of chest pain in all patients with total or subtotal 
oalusion of the infarct-related artery at time 0. The drug 
was given according to one of two scheduler. in a random- 
ized farhion as pan of an ongoing study ofdifferent regimens 
of n-PA treatment (18): either as four bolus iojectioos of IO 
clot lysis mcg.woits (MU) every 20 min over I h with DO 
subsequent infusion or as an infusion of 40 MU over 90 min. 
followed by 4 MU/h over the next 5 h, as recommended by 
Wellcome Research Laboratories at the time of initiation of 
the study. Aspirin (303 mg daily) and diltiazcm (60 mg every 
8 h) were administered from the 9.7 nin time paint. 
Blood snmpks. Blood saples for plasminogen activator 
inhibitor activity, van Willcbrand factor and C-reactive 
protein were taken before r&PA administration and at pre- 
cise 24, 48 and 72 h intervals from the time of entry lo the 
study; a further morning sample was taken after 90 days. 
Samples were taken every 4 h over the first 24 h for 
determination of the myocardial isoenzyme of creatine ki- 
nose (CK MB). fibrinogen. plssminogcn and fibrin-specific 
degradation products. 
Blood was drawn by direct venipuncture after minimal 
woostasis. After the first 2 ml of blood was discarded, 9 ml 
was transferred into cooled plastic tubes containing I ml of 
0.109 M Irisodium citrate. To prevent in vitm fibrin(ogenlo. 
lysis. polyclonal antibodies to r&PA were added to the 
appropnale lubes al a concenlntian shown to block the in 
vitro eEccts of up to 5 pg of R-PA per ml of plasma (19). 
Platelet-poor plasma was obtained by cold (4°C) ccntrifoga- 
lion at 1.300 X g for 20 min. Plasma aliquots were soap 
frozen within I h of blood collection and stored at -7OY 
Laboratory invesligslii. The 24 h continuous ECG 
recordings were analyzed using the Marquette Boo0 laser 
system. A marker indicating the start of rt-PA administration 
was recorded. The time for ST segment elevation to de- 
crease to 50% of maximum. measured from the onset of 
rt-PA treatment, was taken 8s an indirect assessment of 
coronary artery patency (20) and of resolving wtttc myocar- 
dial &hernia. 
Plasma plamn~btngen ocriveror inhibiror arrivity was de- 
termined by titration with purified double chain I-PA (Orga- 
non Tcknika. Cambridge. England) using a parabolic rate 
chromogenic assay. as previously described (21). Values arc 
expressed in 1U of I-PA activity (22) required to neutralize 
the inhibitor activity of I ml of plasma (IUm-‘1. The 
normal range in morning (8 4h4 to IIt 4~) samplc~ win 
between < 1 and 20 ItJm-’ (4.23). 
To assess the correlation between the level\ of plarmino- 
gen activator inhibitor activity and immunore~cove plarnw 
nogen activator inhtbrar-I, the concemraion of plammo- 
gen activator inhihitar-I antigen (ng ml- ‘1 wun\ mcarurcd m 
40 consecutive samples using a specific enzyme-lmked nn- 
munosorbent Assam !‘!‘I-!E!!r- P.&I. Fiooool. Umea. Swe- 
enzyme-linked i&nunosorheot assay of Inp;rslev (24j. Val- 
ues are expressed as a percent of a Tooled normal plasma 
(Immune. Sevenoaks. England), with IMl% corwpondtng 
to I lU.ml-’ (nom~al range 5010 to 150X normill plasmal. 
Plasma concenrrarions nf C-rnrrrivr pro&v were deter- 
mined by an immunoturbidimetric method (RA Systems. 
Technicon method SM4-0183B87. Basingstoke. England) 
Values are expressed in mg.liter-’ lnormal range 0 to 
IO mgliter-‘). 
?iasma CK MB activity was measured kinc!ically afta 
it~~munoinbibition (CK MB NAGactivitv kit. Boehrinwr 
Mannheim. Lewea, England) and enpreised in IU.liter- I. 
The area under the 24 h activity cuwe was taken as an 
estimate of infarct size (25). 
Plasmafibrinonen concenmruriuns wrc measured by clot- 
rate BSSBV 126) and exoressed in clitrr-’ inormal rance 2 to 
4 gliter”). Plasmin&eo conc&tions in pIa& were 
determined by chromogenic assay using streptokinase as an 
activator (Coatest pkuminogen kit. Kabivitrum. Uxbridge. 
England) and expressed as a percent of the pooled normal 
plasma included in the kit Inormal range 75% to 125% normal 
plasma). Plasma concentrations of fibrin-specific degrada- 
tion products were determined by latex agglutination using 
monoclooal antibodies to the awiei!ic cross-linked fibrin 
fragment Ddimer (Mabco Dime&t. Portan Products, Sai- 
isbury. England) and expressed in ng.ml-’ (nomnl range 0 
to 200 ngml-‘). As an index of the degree of fibrin(ogen)o- 
lysio, fibrinogen, plasminogen and D-dime, concentrations 
were measured 8 h afier the start ofrt-PA administration sod 
compared with the pretreatmeni levels. 
The interassay coefficient of variation was <IO% for all 
assays. All laboratory investigations were performed witb- 
out knowledge of clinical data. 
Statis~ieal nalysis. Values are expressed as mean values 
+ SEM. Thi Kolmogorov-Smirnov one sample normality 
test was applied to all variables; only C-reactive protein did 
not show a normal distribution and was analyzed after 
logarithmic transiorrroation. Frequencies of observations 
were analyzed by Fisher‘s one-tailed exact probability test. 
Correlations between two variables were calculated by sim- 
ple linear regression. Differences between continuous vari. 
ables were compared by Student‘s twu-tailcd paired or 
unpwcd , IC\IX as appropriate. S~gmficnnce wax defined as 
pron5. 
Results 
Patient characteristics and ru~mups (Tabfe I). Between 
September 1987 and !anuary 1989. 28 consecutive patients 
met the swdv‘< inclusion criteria. Four patients were ex- 
cluded for lack of blood sample collection: In Ihe remaining 
24 oatients I I7 male, 7 female lmean see SR f 2 wars. raw 
36 ;o 711). the stadard I2 lead ECGbn ad&ion showed 
ST segment elevaion in the anterior or anterolateral leads in 
9 cases nod in the inferior or inferolateral leads in 13: 
changes of true acute posterior infarction xere present in 2. 
Comnn~ on&rap@ pwfornwd before rr-PA odriris- 
rrarbw showed total occlusion of the left anterior descending 
coronary artery in 5 ;atients. oithe right coronary artery in 
IO and of the left circumflex coronary artery in 4. A subtotal 
occlusion c?the left anterior dexwdinp. aner/ was present 
i:! two pabents and of the right coro&y a&y in three. 
Twelve patients were randomly assigned to the n-PA infu- 
sion regimen and I2 to the balus regimen. The mean interval 
from the onset of continuous chest pain to the stan of R-PA 
admintstration was I95 + I7 min (range .94 to 360). 
Augioqrrpby performed 39 ntin after the start of H-PA 
odminirrrnrion showed a patent infarct-relatLd aRery in I6 
patients (patent artery g&p). including the 5 patients with 
subtotal occlusion at time 0. and a~ occluded artery in 8 
patients Ioccluded artery group). Baseline characterieics 
including age. gender. duration of symptoms at the stan of 
rt-PA treatmcrd and mode of R-PA administration did not 
differ stgnificantly between the two groups (Table I). 
Creatine kbwe and ECG data. Plasma CK k4B inte- 
grated over the first 24 h was 2.IW + 373 IU~liter-’ in the 
patent artery group compared with 4.295 + 1.364 IUGter~ 
in the occluded artery group (p = 0.051. Peak CK MB did not 
ddfer significantly between the patent and occluded aifery 
L%gure 1. Plasma cancenrtakms fmean values ? SEM) of C-tesc- 
tive protein dur ng the fitsi 3 days after myocatdiai infarction and 
after 90 days in the patent and occluded attety gtaups. 
gtaaps (133 z 27 vets:us 233 ? 75 lU~liter_‘), but time 10 
teach peak CK MB was significantly shorter in the patent 
ancry group (IO + 1.5 h) than in the occluded artery group 
(15 ? 1.5 h. p = 0.05). 
Technically satisfactory 24 h continuous ECG recordings 
were obtained in 19 patients (13 in the patent and 6 in the 
occluded artery group). The time taken for maximal ST 
segment elevation 10 decrease to SO% was 1.4 ? 0.4 h in the 
patent artery group compared with 7.0 2 3.7 h in the 
occluded anety group (p = 0.04). 
C-reactive protein. C-reacrive protein in the enlite gtmtp 
teacheda peakof 2 9mg+tet-‘onday 2, representingan 
8.6fold increase over values on admission (p = O.ooO1). In 
the patent anety group, C-reactive protein on day 3 was 
significantly lower than in the occluded arterv etouo (Fie. I). 
Peak C-tea& protein was also significantiyiow& (3’?? 6 
vetsus 81 2 25 mglitet-‘. p = 0.014) and the time to reach 
peak concentration significandy shorter (45 + 3 vctsus 62 -c 
6 h, p = 0.01) in the patent artery group than in the occluded 
artery group No significant difference in C-tea&e protein 
Table 2. Plasminogen A&alar Inhibitor Activity and van 
Willebtand Factor in All 24 Patiems During the First 3 Days After 
Myocardiat Infarction and After 90 Days 
Figate 2. Plasma plasminogen activator inhibhor {PAI) activiry 
during the htst 3 days after %yoe:tdiat infarction and after 90 days 
in rhe pateal and occladed attety groups. 
was found between the two groups from admission to day 2 
and after 90 days (Fig. I). 
llasminogen activalor inhibit~i and *on Wilkbrand fac- 
tor in all patients (Table 2). In the entire group of patients. 
plasminogen activator inhibitor aclivity increased more than 
twofold from admission lo day I (p = 0.014). Fmm day I ID 
day 2. Ihe activity decreased significantly (p = 0.03) and 
remained below the 24 h peak value on day 3 (p = 0.019) and 
after 90 days (p = 0.003). The correlation between levels of 
plasminogen aclivatot inhibilot activity and pkminogcn 
activamr inhibitor-1 anligen in the 40 tested samples was 
highly significant (r = 0.58. p C 0.0011. 
Because of the known circadian fluctuation of plasmin+ 
gen activaror inhihitoraaivity in plasma (271, this factor was 
analyzed by dividing samples inlo two subgroups of about 
equal number. according to the actual time of day of blood 
collection. Two intervals, fmm II AM lo I I PM, and from 
II PM IO II AM. were chosen because they encompassed, 
respectively. the periods of lowest and peak plasminogen 
activator inhibitor activiiy in young normal subjects (271 and 
older patients with atherosclerosis (28). Ar the time of 
admission, blood samples taken bctwccn I I AM and I I PM 
had significantly lowerplasminogen activatotinhihitoractiv- 
ity compared with samples laken between I I PM and I I AM 
(9 f 2 vetsus 22 + 4 IUm-‘. respectively. p = 0.01). No 
significant difference in plasminogen a&r&t inhibitor a‘:- 
tivity related 10 time of day was found on days I, 2 and 3 
after admission. 
WI Willebrandfiwor f Tub/e 2) did no/Juc~rrafr sigkj- 
mnriy during rhe fjrsr 3 days afm ittfarfarnion. Values on 
admission and days I and 2 were significantly higher &ban 
after 90 days (p < 0.01). No correlation war found between 
the levels of van Willehnnd faclor on admission and the 
duration of symptoms before the first blood colle&n (r = 
0.05). 
Fbismbmgen activator inhibitor-l and vnn Willebrend fat- 
tar in palknt subgroups. Plasminogcn activator inhlhllor 
activity (Fig. 21 did not differ rignificanrly between Ihe 
patients with patent and occluded art&s XI admission and 
on day I. On day 2. however. the activity was more rhan two 
limes lower in the patent artery group ip = 0.05) and on &I) 
3 it was more than seven times lower lp = 0.0171 than value\ 
in the occluded artery group. No significant diffcrcncc in 
plasminogen activator inhibitor activity was found beraecn 
the two groups after 90 days. 
“on Willefimnd fuuc/or ww signijmt~ly fowrr ir, rhr 
parent urrety grurcp compared with the occluded arrery 
group onday 1 (p = 0.001) and day 3 Ip = 0.008) (Fig. 3). The 
0 10 72 h averaged concentration was also significantly lower 
in the patent compared with the occluded artery group 1131 
i 9% versus 190.5 r 19% normal plasma. p = tHlt?4). No 
significant difference in van Willebrand factor was found 
between the two groups on admission or on day 2 and after 
90 days. 
Other heme&Gc changes (Table 3). Changes in the 
plasma concentrations of fibrinogen. plasminogen and D- 
dimer 8 h after the start of rt.PA administration were not 
significantly different from pretreatment levels in the patent 
and occluded artery groups. From admission to 8 h. tibrin- 
ogen decreased by 1.36 f 0.3 gliter-’ in the pateni artery 
group and by 2.26 + 0.35 gGter_’ in the occluded artery 
group (p = 0.1). Plasminagen decreased by 41 2 4.2% 
Disrtkssior. 
Rulation between early coronary reperfusian and phasnaa 
Fnclnr\. Thl\ study demonrtratcr that coronary artcry pa- 
kncy ,xhievcd up 10 7.5 h from thr onset of qmptoms in 
paticnti with acute myocardinl infarction is ;Ir<ociated with a 
r&&m in the circulating levels of the two procoagulant 
prolcinx plasminogen activator inhibitor-l and van Wille- 
brand fxlor. To our knowledge. rhcsc are the firer human 
data demonstrating the inhibitory effects of coronary reca- 
naliL,\txln on prucvagulant blood components after myocar- 
did rnfarclion. The askalion between the reduction m 
plasma of C-reactive protein dnd that of placminogen accli- 
Y~IUI minhllor activity and von Willebrand factor during the 
firsl 3 dayr after infarction in the patients who had exhibited 
rcc;mali%i~i~on of the tnfarcr-related artery 1s consistent with 
‘hc prcv~~rly described acu!c phze r-c:;nt nature of the 
Fa\l-xrmg plasmirqen activator inhibitor (3.4.12.13) and 
van Willcbrxnd factor (5.14. IS). Our rcsulls also suggest that 
the duration of response of plasminogen activator inhibitor-k 
and the lsvcls of van Willebmnd factor re!lect the magnitude 
of the acute phase response. 
AI the time of admission and after YU days. plasminogen 
activator inhibitor activity. van Willebrand factor and C-re- 
actwe prorem concentrations were not rignificantly different 
in the palients with a patent artery compared with those with 
an occluded artery (Fig. I to 31. The !evels of these three 
proteins. therefore. do not appear to have influenced the 
outcome of thrombolytic therapy. 
The administration of r&PA may have had some effects 
on the plasma concentrations of plasminogen activator in- 
hibitor nctiviry, van Willebrand factor and C-reactive pro- 
kin. Thehe effects. if oresent. Presumably would have been 
diatributcdcqually ambngthcerttiregrou~ofpatientsreceiv. 
ing rt-PA. Therefore. it is unlikely that the significant c’iffer. 
ences in the plasma levels of these factors in patienti with 
Table 3. Fibrinogen. Plasminogen and D-dimer Concenlrntwnh Bckre and 8 h Mer rt-PA in the 
‘Two Grouos cl Patients 
and without a patent infarct-related anery at 90 min were 
related to R-PA treatment. 
The diRerewes in plasminogen activator inhibitor activ- 
ity. van Willebmnd factor and C-reactive protein between 
the patent and occluded artery groups were not associated 
with significant differences in the acute changes in fibrinogen 
and plasminogen (Table 31. The fibrinogen and plasminogen 
consumption consequent to thrombolytic treatment pre- 
cluded any assessment of these two acute phase proleins in 
response to myocardial infarction. The lack of a significant 
difference between the patenr and occluded artery groups in 
the increase in circulating D-dimer concentration at the end 
of HA adnintstration suggests that Ddimer is derived 
mainly from the breakdown of circulating soluble fibrin. 
rather than soictly from the coronary thromhus (291. 
Cmtparison wilh prevkws studies. To our knowledge. 
onl!~ me other study (30) has related the degree of acute 
phe:;: reaction to cnronary recanalization after thrombolytic 
tree :I xwt. In that wdy, successful reperfusion assessed by 
ind.rect criteria was associated with a marked reduction in 
the response of C-reactive protein. but the reduction was 
independent of infarct size estimated by serial CK MB and 
radionuclide methods. The authors (30) concluded that rapid 
reperfusion of the infarcted myocardium may have changed 
the evolution of infarction so that the usual acute phase 
response did not take place. Although this possibility cannot 
be excluded, the results of our study and of previous 
investigations (31.32) strongly suggest a correlation between 
enzymatically estimated infarct size and magnitude of the 
C-reactive protein response. 
Different patternsof plasminagen aelivator Inhibitor-l, van 
Wilkbrand factor and C-reactive proleln. The pattern of 
response of the three acute phase reactants differed fmm 
each other. both when considered in the entire group of 
patients and in relation to coronary patency. In the entire 
group, the interval required for each protein to reach maxi- 
mal value over the firs; 3 days after infarction ranged from 
the time of admission for van Willebrand factor to day I for 
plasminogen activator inhibitor activity and day 2 for C-re- 
active protein. The facts that the van Willebmnd factor 
concentration was already high at the time of admission and 
that plasma concentrations did not correlate with the dura- 
tion of symptoms at this time indicate either that van 
Willebrand factor peaked very soon after coronary occlusion 
or that increased concentrations of this factor preceded the 
clinical onset of myocardial infarction. 
In the group as a whole, plasminogen activator inhibitor 
activity on admission was significantly higher in blood taken 
between I I PM and II AM than in blood taken between I I AM 
and 11 PM. This finding sogge~ts that within 6 h of sympto- 
matic onset of myocardial hfarction, the physiologic circa 
dian rhythm of the fast-acting plasminogen activator inhibi- 
tor is preserved. and that inhibitor activity is higher during 
the early morning hours than in the afternoon or evening 
(27). The lack of such a difference in the samples taken over 
the next 3 days suggests that in this acute phase period, the 
circadian rhythm is being overridden by the considerable 
stimulation of plasminogen activator inhibitor-l induced by 
myocardml damage. 
In relation to coronary infarct-related aflery patency, the 
early response of plasminogen activator inhibitor activity in 
the palients who had recanalizalion of the artery was re- 
duced more in duration than in amplitude by comparison 
with findings in palienls in Ihe occluded artery group. In 
contrast. the van WiNebrand factor response in the patent 
artery group was reduced more in amplitude than in dun 
tion. whereas the response ofC-reactive protein was both of 
smaller amplitude and of shorter duration compared with 
findings in the occluded artery group. Such distinct patterns 
of respons; suggest the existence of different mechanisms 
controlling the levels and turnover of the lhree proteins. In 
cultured human endothelial cells, the plasminogen activator 
inhibitor-l and van Willehrand factor response to cytokines 
or other stimulants lends suppat to the d&rent time course 
observed in viva. In the culture medium. increased phsmi- 
nogen activator inhibitor activity is determined by de nova 
protein synthesis. with a time lag of several hours (3?-36). In 
contrast. on stimulation in vitm, van Willebrand factor can 
be released rapidly from an in:iacellular storage pool. rep 
resented by the Weibel-Palade bodies of endothelial cells, 
without de now protein synthesis (37.38). For the relatively 
slower C-reactive protein response. induction of its synthe- 
sis in hepatoeytes is probahl; involved. 
Relation between inflammatory response and i&ret size. 
Previous studies (3-5.12-15,391 have shown that plasmino- 
ten activator inhibitor acrivitv and van Willebrand factor 
&reax in many clinical conditions characterized by acute 
phase reactions. A correlation between the magnitude of the 
acute phase response (estimated by serial C-reactive protein 
cancenttationsjand infarct size (awssed by enzyme deter- 
minations or bv thallium-201 sinele ohoton emission tomo~ 
whyI is weli documented (3i-dl. In our series, peak 
C-reactive protein and duration of the response were also 
significantly reduced in the patients with early coronary 
patency and smaller infarct size compared with the occluded 
artery group. The patent artery group also showed a signif- 
icantly faster resolution of acute ischemia, as assessed by 
lime to reach half-maximal ST segment elevation. 
Although the pthogenesis of the acute phase response is 
not complelely understood. it is closely related to the 
production of medialo~~molecules. such as intedeukin-I (40) 
and tumor nicrosis factor (41). by blood monocytes and 
tissue macrophages, which are capable of triggering the 
lranscription. synthesis (II release of C-reactive protein from 
hepatocyres (40). and of plnsminogen activator inhibitor-l 
(33-361 and van Willebrand factor (37) from vascular endo- 
thelium. It is likely that acute myocardial damage leads to 
the production of these inflammatory mediators. which 
stimulate the release of aale phase rei~ct.mt\. and ihri rhc 
duration and magnitude of this &wlitioo are prupor!ion:il 
tothe c~fent of myoiaidial injury and t;ccrosi\ Thir ioocep~ 
is supported by the recent detecdun of circulating tumor 
necrosis factor-o in patients with a large myocardral mfwc~ 
don (42). suggesting il quantilalive rclauon bctwccn Ihc 
extent of myocardial oecroris and the release of cyxokmw 
into the circulation. 
On the basis of our resu/Is and of Ihe prccedmg coowJ- 
erations we suggest hat the curtadmrnl of the platmmopcn 
activator inhibitor-l and van Willehrand factor rc\ponw IS 
consequent to lhe limilatmn of myoiardial achemm and 
infarction as a result of successful coronary IhromholyGs 
and to the concomitantly reduced axle pharr rraclwn 
associated presumably with a sm~llcr cytokmc inductwn. 
Conclusions and clinical implications. In view of the pro- 
coagulant properties of plasminogen activator inhibilor-I 
and van Willehmnd factor. the significant reduction in the 
circulating levels of these two proteins after coronary reca- 
nalization may be of clinical relevance by lowering Ihe ribk 
of local and systemic thromboembolic comphcations durmg 
the acute phase of myocardial infwtion. Indeed. il IS 
conceivable that Ihe lower mortalilv rate ix palienls wth 
acute infarction receiving early thrombolytic therapy (43.34) 
may he partly due to the beneficial systemic effects of 
coronary recanalization on the hemostatic balance. Attenu- 
ation of the early postinfarction procoagulant state may thus 
conslitule a favorable counterpan of succesrful coronary 
thrombolysis that goes beyond the reduction of infarct size 
itself. 
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